Limits...
Endocannabinoids modulate human blood-brain barrier permeability in vitro.

Hind WH, Tufarelli C, Neophytou M, Anderson SI, England TJ, O'Sullivan SE - Br. J. Pharmacol. (2015)

Bottom Line: Endocannabinoids alter permeability at various epithelial barriers, and cannabinoid receptors and endocannabinoid levels are elevated by stroke, with potential neuroprotective effects.Anandamide (10 μM) and oleoylethanolamide (OEA, 10 μM) decreased BBB permeability (i.e. increased resistance).The endocannabinoids may play an important modulatory role in normal BBB physiology, and also afford protection to the BBB during ischaemic stroke, through a number of target sites.

View Article: PubMed Central - PubMed

Affiliation: School of Medicine, University of Nottingham, Royal Derby Hospital, Derby, UK.

No MeSH data available.


Related in: MedlinePlus

The effects of various concentrations of AEA either before (A) (n = 7–12 inserts from four separate experiments) or after (C) (n = 9–10 inserts from four separate experiments) 4 h OGD on permeability in the BBB, with corresponding AUC (B and D). Data are given as mean ± SEM. #, * (10 μM) † (30 μM), P < 0.05; compared with vehicle; one-way anova with Dunnett's test.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4459020&req=5

fig04: The effects of various concentrations of AEA either before (A) (n = 7–12 inserts from four separate experiments) or after (C) (n = 9–10 inserts from four separate experiments) 4 h OGD on permeability in the BBB, with corresponding AUC (B and D). Data are given as mean ± SEM. #, * (10 μM) † (30 μM), P < 0.05; compared with vehicle; one-way anova with Dunnett's test.

Mentions: Exposing the BBB to 4 h OGD increased permeability as shown by a reduction in TEER of approximately 35% (Figure 4). AEA did not alter the BBB permeability response to OGD when applied before (Figure 4A and B) or after the OGD protocol (Figure 4C and D).


Endocannabinoids modulate human blood-brain barrier permeability in vitro.

Hind WH, Tufarelli C, Neophytou M, Anderson SI, England TJ, O'Sullivan SE - Br. J. Pharmacol. (2015)

The effects of various concentrations of AEA either before (A) (n = 7–12 inserts from four separate experiments) or after (C) (n = 9–10 inserts from four separate experiments) 4 h OGD on permeability in the BBB, with corresponding AUC (B and D). Data are given as mean ± SEM. #, * (10 μM) † (30 μM), P < 0.05; compared with vehicle; one-way anova with Dunnett's test.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4459020&req=5

fig04: The effects of various concentrations of AEA either before (A) (n = 7–12 inserts from four separate experiments) or after (C) (n = 9–10 inserts from four separate experiments) 4 h OGD on permeability in the BBB, with corresponding AUC (B and D). Data are given as mean ± SEM. #, * (10 μM) † (30 μM), P < 0.05; compared with vehicle; one-way anova with Dunnett's test.
Mentions: Exposing the BBB to 4 h OGD increased permeability as shown by a reduction in TEER of approximately 35% (Figure 4). AEA did not alter the BBB permeability response to OGD when applied before (Figure 4A and B) or after the OGD protocol (Figure 4C and D).

Bottom Line: Endocannabinoids alter permeability at various epithelial barriers, and cannabinoid receptors and endocannabinoid levels are elevated by stroke, with potential neuroprotective effects.Anandamide (10 μM) and oleoylethanolamide (OEA, 10 μM) decreased BBB permeability (i.e. increased resistance).The endocannabinoids may play an important modulatory role in normal BBB physiology, and also afford protection to the BBB during ischaemic stroke, through a number of target sites.

View Article: PubMed Central - PubMed

Affiliation: School of Medicine, University of Nottingham, Royal Derby Hospital, Derby, UK.

No MeSH data available.


Related in: MedlinePlus